Press Releases
EASTGATE BIOTECH CORP. NAMES NEW PRESIDENT
January 20, 2015
SALT LAKE CITY and TORONTO, January 20, 2015 (PRNewswire/-) Eastgate Biotech Corp., formerly EastGate Acquisitions Corporation (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules has appointed ...
Read moreNEW STOCK SYMBOL ETBI
December 15, 2014
EASTGATE ACQUISITIONS ANNOUNCES NAME CHANGE TO EASTGATE BIOTECH CORP. AND NEW STOCK SYMBOL SALT LAKE CITY and TORONTO, December 15, 2014 (PRNewswire/-) Eastgate Biotech Corp., formerly EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel ...
Read moreCompany’s Proprietary Intraoral Lorazepam Spray
November 3, 2014
EASTGATE ACQUISITIONS ANNOUNCES POSTER PRESENTATION OF THE COMPANY’S PROPRIETARY INTRAORAL LORAZEPAM SPRAY AT THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS (AAPS) CONFERENCE SALT LAKE CITY and TORONTO, November 3, 2014 (PRNewswire/-) EastGate Acquisitions Corporation ...
Read moreEASTGATE ACQUISITIONS AUGMENTS ITS SUB-MICRON SELF-NANOEMULSIFYING PLATFORM TECHNOLOGY
August 15, 2014
Broad spectrum of delivery forms is directed towards improving patient complianceSALT LAKE CITY and TORONTO, August 15 , 2014 (PRNewswire/-) EastGate ...
Read moreEASTGATE ACQUISITIONS ENTERS INTO A LICENSE AGREEMENT WITH PURINE PHARMA LLC FOR MARKETING AND DISTRIBUTION OF ITS NUTRACEUTICAL AND CONSUMER PRODUCT LINE
July 29, 2014
SALT LAKE CITY and TORONTO, September 29, 2014 (PRNewswire/-) EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of novel formulations and alternative dosage forms of existing biologically active molecules, announces that it has entered into a licensing ...
Read moreA transmucosal Lorazepam spray for treatment of acute seizures: Summary
July 29, 2014
The estimated annual incidence of prolonged epileptic seizures (status epilepticus) in the USA is about 150,000 cases and approximately 400,000 patients that suffer from repetitive seizures. These emergency conditions lead to 40,000 deaths in the USA every year. Control of status epilepticus and repetitive seizures ...
Read moreEastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology
July 29, 2014
New pharmaceutical development opens up entry into blockbuster marketsSALT LAKE CITY and TORONTO, July 29, 2014 /PRNewswire/ -- EastGate AcquisitionsCorporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug deliveryinnovations in the development of improved novel formulations and alternative...
Read moreEASTGATE ACQUISITIONS RECEIVES RESEARCH GRANT FROM ONTARIO BRAIN INSTITUTE
June 25, 2014
SALT LAKE CITY and TORONTO, June 25, 2014 /PRNewswire/-- EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules ...
Read moreEASTGATE ACQUISITIONS ENTERS INTO WORKING COLLABORATION WITH LEADING NEUROLOGIST AT TORONTO WESTERN HOSPITAL
June 17, 2014
SALT LAKE CITY and TORONTO, June 17, 2014 /PRNewswire/ -- EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules expands on its pharmaceutical ...
Read moreEASTGATE ACQUISITIONS ANNOUNCES PRESENTATION AT STE’S 3 ANNUAL MICROCAP INVESTOR CONFERENCE
May 28, 2014
SALT LAKE CITY and TORONTO, May 28, 2014 /PRNewswire/ -- EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules, announced today that it will be ...
Read more